(Aceclofenac + eperisone SR) is under clinical development by NVP Healthcare and currently in Phase III for Muscle Spasm. According to GlobalData, Phase III drugs for Muscle Spasm does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Aceclofenac + eperisone SR) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Aceclofenac + eperisone SR) overview
A fixed-dose combination of aceclofenac and eperisone SR is under development for the treatment of acute low back pain, muscle spasm and musculoskeletal disorder. The drug candidate is administered orally. Aceclofenac acts by targeting cyclooxygenase-2 (COX-2) enzyme. Eperisone acts by targeting alpha 1 adrenergic receptor, alpha 2 adrenergic receptor, muscarinic acetylcholine receptor (mAChR) and serotonin (5-HT) receptor. It is an incrementally modified drug (IMD).
NVP Healthcare overview
NVP Healthcare formerly Navipharm, develops novel pharmaceuticals products and microbiomes. NVP Healthcare is headquartered Suwon, Gyeonggi, South Korea.
For a complete picture of (Aceclofenac + eperisone SR)’s drug-specific PTSR and LoA scores, buy the report here.